Michael Dybbs
SelectiveNamed in filings at Samsara BiocapitalOn the current fund
- Board seats filed
- 8
- Named on a board
- 2
all filings on record
Named in filings at Samsara BiocapitalOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Claris Biotherapeutics | Biotech & pharma | November 2025 | Partners Innovation |
| Abcuro | Biotech & pharma | February 2025 | New Leaf, Partners Innovation |
| Delfi Diagnostics | Not yet classified | June 2022 | None on file |
| Nkarta | Biotech & pharma | August 2019 | None on file |
| SUTRO BIOPHARMA | Biotech & pharma | May 2018 | SV Life Sciences, Virtuoso-mccarran |
| Levo Therapeutics | Not yet classified | August 2017 | None on file |
| Principia Biopharma | Biotech & pharma | July 2015 | Orbimed Asia Partners, Orbimed Genesis |
| Versartis | Not yet classified | February 2014 | Advent Life Sciences |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Michael Dybbs on the board, based on 5 filed seats with a verified or cited source.
3 more filed seats not yet classified, left out of the shares above.